At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BMEA Biomea Fusion, Inc.
Pre-Mkt 03-04 08:46:11 EST
1.33
-0.04
-2.92%
盘前1.33
+0.00-0.01%
08:46 EST
High1.37Low1.25Vol1.15M
Open1.32D1 Closing1.37Amplitude9.12%
Mkt Cap94.04MTradable Cap76.13MTotal Shares70.70M
T/O1.50MT/O Rate2.01%Tradable Shares57.24M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Biomea Fusion Updates Corporate Presentation on Metabolic Pipeline
TIPRANKS  ·  02-25
Biomea Fusion Updates Corporate Presentation on Metabolic Pipeline
Biomea Fusion to Present at Oppenheimer Healthcare Life Sciences Conference
Reuters  ·  02-19
Biomea Fusion to Present at Oppenheimer Healthcare Life Sciences Conference
Biomea Fusion to Participate at Upcoming Investor Conferences
GlobeNewswire  ·  02-19
Biomea Fusion to Participate at Upcoming Investor Conferences
Biomea Fusion Highlights Diabetes Pipeline at JPM Conference
TIPRANKS  ·  01-15
Biomea Fusion Highlights Diabetes Pipeline at JPM Conference
Biomea Fusion initiated with a Buy at Rodman & Renshaw
TIPRANKS  ·  01-14
Biomea Fusion initiated with a Buy at Rodman & Renshaw
Biomea Fusion Is Maintained at Buy by D. Boral Capital
Dow Jones  ·  01-13
Biomea Fusion Is Maintained at Buy by D. Boral Capital
Biomea Fusion Inc. Announces 2026 Strategy Focusing on Advancing Icovamenib and BMF-650 Clinical Programs, Initiating Phase II Trials in Type 2 Diabetes and Continuing Oral GLP-1 Candidate Development
Reuters  ·  01-12
Biomea Fusion Inc. Announces 2026 Strategy Focusing on Advancing Icovamenib and BMF-650 Clinical Programs, Initiating Phase II Trials in Type 2 Diabetes and Continuing Oral GLP-1 Candidate Development
Director and Officer Rainer M. Erdtmann Acquires Common Shares of Biomea Fusion Inc
Reuters  ·  2025-12-16
Director and Officer Rainer M. Erdtmann Acquires Common Shares of Biomea Fusion Inc
Biomea Fusion Highlights Icovamenib Data at WCIRDC 2025
Reuters  ·  2025-12-10
Biomea Fusion Highlights Icovamenib Data at WCIRDC 2025
BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies
Reuters  ·  2025-12-06
BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies
BUZZ-U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Ulta Beauty, Victoria's Secret
Reuters  ·  2025-12-05
BUZZ-U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Ulta Beauty, Victoria's Secret
BUZZ-Biomea Fusion rises as diabetes drug shows promise
Reuters  ·  2025-12-05
BUZZ-Biomea Fusion rises as diabetes drug shows promise
Biomea Fusion Reports Durable Glycemic Improvements with Icovamenib in Type 2 Diabetes Trial
Reuters  ·  2025-12-05
Biomea Fusion Reports Durable Glycemic Improvements with Icovamenib in Type 2 Diabetes Trial
Biomea Fusion Presents Covalent-111 Study Results at the 23Rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Wcirdc)
THOMSON REUTERS  ·  2025-12-05
Biomea Fusion Presents Covalent-111 Study Results at the 23Rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Wcirdc)
Interim CEO Michael J.M. Hitchcock Reports Acquisition of Biomea Fusion Inc. Common Shares
Reuters  ·  2025-12-05
Interim CEO Michael J.M. Hitchcock Reports Acquisition of Biomea Fusion Inc. Common Shares
Biomea Fusion Inc. CEO and Director Rainer M. Erdtmann Reports Acquisition of Common Shares
Reuters  ·  2025-12-03
Biomea Fusion Inc. CEO and Director Rainer M. Erdtmann Reports Acquisition of Common Shares
Biomea Fusion Unveils Positive Long-Term Icovamenib Data in Type 2 Diabetes at WCIRDC
Reuters  ·  2025-12-02
Biomea Fusion Unveils Positive Long-Term Icovamenib Data in Type 2 Diabetes at WCIRDC
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23Rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Wcirdc)
THOMSON REUTERS  ·  2025-12-02
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23Rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Wcirdc)
Biomea Fusion Grants Stock Options to New Employee Under 2023 Inducement Plan
Reuters  ·  2025-12-02
Biomea Fusion Grants Stock Options to New Employee Under 2023 Inducement Plan
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  2025-12-02
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Introduction

Company Name.
Biomea Fusion, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Issue price:
--